Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (301-310 of 516) with videos related to

Pageof 52
Sort By:
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 3, 2018
Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain AmyloidosisM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Transplantation and Cellular Therapy|May 13, 2022
Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell TransplantSurbhi Sidana, Amylou C Dueck, Gita Thanarajasingam, et al.
Haematologica|April 21, 2018
Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantationM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Haematologica|February 13, 2009
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosisAlan H Bryce, Rhett P Ketterling, Morie A Gertz, et al.
Blood|August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaS Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
Blood Cancer Journal|November 25, 2018
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research ProjectSaad Z Usmani, Antje Hoering, Michele Cavo, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 2, 2025
Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian CountriesUday Yanamandra, Celine Raphael, Roopika Peela, et al.
Frontiers in Oncology|June 1, 2022
Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like CellsHarish Kumar, Suman Mazumder, Neeraj Sharma, et al.
Blood Cancer Journal|November 27, 2021
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosisAlissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Pageof 52

Showing results (301-310 of 516) with videos related to

Sort By:
Pageof 52
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 3, 2018
Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain AmyloidosisM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Transplantation and Cellular Therapy|May 13, 2022
Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell TransplantSurbhi Sidana, Amylou C Dueck, Gita Thanarajasingam, et al.
Haematologica|April 21, 2018
Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantationM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Haematologica|February 13, 2009
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosisAlan H Bryce, Rhett P Ketterling, Morie A Gertz, et al.
Blood|August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaS Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
Blood Cancer Journal|November 25, 2018
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research ProjectSaad Z Usmani, Antje Hoering, Michele Cavo, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 2, 2025
Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian CountriesUday Yanamandra, Celine Raphael, Roopika Peela, et al.
Frontiers in Oncology|June 1, 2022
Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like CellsHarish Kumar, Suman Mazumder, Neeraj Sharma, et al.
Blood Cancer Journal|November 27, 2021
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosisAlissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Pageof 52